Search

everythinglearnresearchcommunity

for

Search:↓

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

The safety and effectiveness of RU-58841 as a hair loss treatment, with some users reporting side effects like chest pains, while others had positive results. The original research on RU-58841 was likely stopped due to financial issues, not safety concerns.

A 27-year-old male with ADHD is experiencing hair thinning and is starting a treatment with topical finasteride (0.025%) and minoxidil (5%). He is addressing high prolactin levels and low vitamin D, while managing side effects from ADHD medication.

Gizzela is unsure about the dosage and frequency of copper peptides and asks if they can be used with Stemoxydine. They seek advice on applying these treatments together.

Latanoprost is discussed as a potential hair loss treatment, noted for its synergy with minoxidil and 5-AR inhibitors, but concerns include its effectiveness on scalp hair, cost, and potential skin darkening. Some users express interest in trying latanoprost or bimatoprost despite limited real-world evidence.

Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.

The user has been using oral finasteride and minoxidil for hair loss but is considering switching back to topical minoxidil due to persistent scalp issues. Another user suggests an anti-inflammation regimen and oral dutasteride.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The user is considering switching from a topical minoxidil and finasteride solution to oral minoxidil to improve hair growth, while maintaining oral finasteride. They are concerned about potential shedding and whether they can maintain any new growth.

RU58841 cured seborrheic dermatitis, oily scalp, dandruff, and scalp pain, improving hair health when combined with Minoxidil. Another user noted diet impacts their seborrheic dermatitis and that finasteride hasn't changed their condition.

The user checked iron, ferritin, B12, zinc, testosterone, DHT, and estrogens to understand hair loss causes and the effects of dutasteride. They also noted increased heart rate and paleness with oral minoxidil.

Facing fears and making a doctor appointment to get more info on individual hair loss cases, as well as the discussion of potential treatments such as Finasteride/Dutasteride, Minoxidil, or RU58841.

Dutasteride and finasteride have similar risk profiles despite Dutasteride blocking more types of 5AR in the brain. Some users report no mood issues with either drug, and it is suggested that Dutasteride's larger molecular size may limit its ability to cross the blood-brain barrier.

The conversation discusses hair loss treatments, including the use of 2.5mg Dutasteride, 1mg Finasteride, and Minoxidil 5%, with concerns about side effects like water retention and facial changes. The user is considering alternative Minoxidil applications, such as microneedling and sublingual Minoxidil, to minimize side effects.

A trans woman is experiencing hair loss and is considering treatments like cyproterone, dutasteride, and oral minoxidil. She is concerned about potential hair growth on her face, chest, or legs due to minoxidil.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

A user is concerned that prolonged use of valisone (betamethasone) and clotrimazole solution for scalp dermatitis may be causing hair thinning and loss. They noticed thinning in the area where the solution was applied.

Topical diazoxide may be a promising hair regrowth treatment, especially for those who don't respond to minoxidil, as it activates potassium channels without needing sulfation. It appears safe for topical use, avoiding systemic effects seen in oral use.

The user stopped using minoxidil due to headaches, which returned upon resuming the treatment, leading to hair shedding concerns. Alternatives like finasteride and diluted minoxidil were suggested by others experiencing similar side effects.

The user started using topical latanoprost and dutasteride, experiencing significant hair shedding and scalp itchiness, possibly due to an allergic reaction. They are considering stopping the treatment if the shedding is linked to an allergy.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

A user experienced a loss of libido and anhedonia after severe dietary restriction while on Finasteride and Minoxidil for hair loss. They are considering reducing the Finasteride dose or taking a break to see if symptoms improve.

A long-term finasteride user experienced side effects like sexual dysfunction, dry eyes, muscle weakness, and brain fog, which improved when they stopped the medication. They decided to stop finasteride again, questioning if maintaining hair was worth the negative impact on their well-being.

The user is using oral minoxidil for hair growth and is considering adding topical latanoprost, but is concerned about potential eye color change. They are seeking advice on the effectiveness of latanoprost for hair thickening and the risk of eye color change.

People discuss hair loss treatments like finasteride, dutasteride, and minoxidil, debating side effects and effectiveness. Concerns about side effects, especially sexual ones, are common, with varying opinions on dosing strategies.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

A bodybuilder discusses homebrewing Minoxidil and RU58841 using propylene glycol or MCT. They inquire about the feasibility and potential risks of these methods.

Prolonged use of topical minoxidil and finasteride can lead to neuroendocrine and autonomic dysfunction, causing severe sensitivity and side effects. Recovery involves avoiding these treatments, supporting neurosteroid recovery, calming the sympathetic system, and rebuilding scalp health naturally.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

The user has been using oral minoxidil, finasteride, and dutasteride for hair loss, along with supplements like arginine and collagen, but has seen no improvement. They also suffer from chronic eczema, which may contribute to hair loss, but it is considered reversible.